X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.
Lead Product(s): Cetuximab Sarotalocan Sodium
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2023
Details:
The trial conducted for ASP-1929 photoimmunotherapy with fluorescence imaging, an antibody-dye conjugate binds to epidermal growth factor receptor, will assess efficacy and safety of surgical tumor resection in patients with operable primary or recurrent HNSCC or cuSCC.
Lead Product(s): ASP-1929 Photoimmunotherapy
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shimadzu
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Rakuten Medical is conducting a global Phase 3 multi-center clinical trial with ASP-1929 IV Infusion (cetuximab sarotalocan sodium) in patients with recurrent head and neck squamous cell carcinoma.
Lead Product(s): Cetuximab Sarotalocan Sodium
Therapeutic Area: Oncology Product Name: Akalux
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Momentum Capital Markets
Deal Size: $166.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 28, 2021
Details:
The data concluded that RM-1929 photoimmunotherapy showed a manageable safety profile in rHNSCC and showed tumor response in the heavily pre-treated patient population was clinically meaningful and warranted further investigation.
Lead Product(s): Cetuximab-conjugated IRDye 700DX
Therapeutic Area: Oncology Product Name: RM-1929
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
Details:
The trial will enroll three cohorts of patients within distinct populations. Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy.
Lead Product(s): Cetuximab-conjugated IRDye700DX,Pembrolizumab
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
IlluminoxTM technology platform developed ASP-1929 which binds to epidermal growth factor receptors (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck cancer, esophageal cancer, lung cancer, colon cancer, and pancreatic cancer.
Lead Product(s): Cetuximab-conjugated IRDye700DX
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Medlight SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 19, 2020
Details:
Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales.
Lead Product(s): Cetuximab-conjugated IRDye700DX
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2020
Details:
Under the signed MOU, NCC and Rakuten Medical will pursue multiple avenues to advance Illuminox-based cancer therapies. NCC will designate a lead principal who will act as an Illuminox Advisor.
Lead Product(s): ASP-1929
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The National Cancer Center Japan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
